LainiePMartinMD

Oncology • Philadelphia, PA

Physician

Join to view full profile

Dr. Martin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Martin's full profile

Already have an account?

Office
Perelman Center for Advanced Medicine
3400 Civic Center Blvd
Philadelphia, PA 19104
Phone+1 215-614-1850

Fax+1 215-615-3349
Is this information wrong?

Education & Training

Temple University HospitalFellowship, Hematology and Medical Oncology, 2003 - 2006
Boston University Medical CenterResidency, Internal Medicine, 1999 - 2002
Lewis Katz School of Medicine at Temple UniversityClass of 1999

Certifications & Licensure

PA State Medical License 2003 - 2024
MA State Medical License 2002 - 2005

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2009 Oct 28
Completed
Phase 1
Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma Start of enrollment: 2009 Nov 01
Completed
Phase 1
Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2010 Oct 01
Completed
Phase 2
Neoadjuvant Therapy for Ovarian Cancer Start of enrollment: 2010 May 17
Completed
Phase 2
Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors Start of enrollment: 2010 Oct 01
Completed
Phase 1, Phase 2
A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer Start of enrollment: 2010 Dec 14
Completed
Phase 1
Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer Start of enrollment: 2012 Dec 03
Completed
Phase 2
A Study of ENMD-2076 in Ovarian Clear Cell Cancers Start of enrollment: 2013 Sep 01
Completed
Phase 2
Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer Start of enrollment: 2013 Sep 30
Completed
Phase 1
Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2013 Oct 09
Terminated
Phase 1, Phase 2
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2014 Jul 21
Active, not recruiting
Phase 2
A Study Comparing AZD-1775 (MK-1775) and Gemcitabine With Gemcitabine Alone in Ovarian, Peritoneal or Fallopian Tube Cancers Start of enrollment: 2014 Jul 01
VM110 in Detection of Microscopic Tumors: A Phase I Study Start of enrollment: 2017 Oct 12
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

1 citations
Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patien...
Debra L Richardson, Kathleen N Moore, Ignace Vergote, Lucy Gilbert, Lainie P Martin, Gina M Mantia-Smaldone, Cesar M Castro, Diane Provencher, Ursula A Matulonis, Jame...> ;Gynecologic Oncology. 2024 Mar 5
1 citations
Molecular landscape of ERBB2/HER2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions.
Dimitrios Nasioudis, Stefan Gysler, Nawar Latif, Lory Cory, Robert L Giuntoli 2nd, Sarah H Kim, Fiona Simpkins, Lainie Martin, Emily M Ko> ;Gynecologic Oncology. 2024 Jan 1
Next generation sequencing reveals a high prevalence of pathogenic mutations in homologous recombination DNA damage repair genes among patients with uterine sarcoma.
Dimitrios Nasioudis, Nawar A Latif, Emily M Ko, Lori Cory, Sarah H Kim, Lainie Martin, Fiona Simpkins, Robert Giuntoli 2nd> ;Gynecologic Oncology. 2023 Oct 1
2 citations
A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors.
Matthew Zibelman, Alexander W MacFarlane 4th, Kimberly Costello, Thomas McGowan, John O'Neill, Rutika Kokate, Hossein Borghaei, Crystal S Denlinger, Efrat Dotan, Danie...> ;Nature Communications. 2023 Jul 27
4 citations
Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor-Resistant Homologous Recombination-Deficient Ovarian Cancer.
Stephanie L Wethington, Payal D Shah, Lainie Martin, Janos L Tanyi, Nawar Latif, Mark Morgan, Drew A Torigian, Diego Rodriguez, Simon A Smith, Emma Dean, Susan M Domch...> ;Clinical Cancer Research. 2023 Aug 1
5 citations
[18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study.
Austin R Pantel, Sarah B Gitto, Mehran Makvandi, Hyoung Kim, Sergey Medvedv, Joanna K Weeks, Drew A Torigian, Chia-Ju Hsieh, Benjamin Ferman, Nawar A Latif, Janos L Ta...> ;Clinical Cancer Research. 2023 Apr 14
16 citations
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemos...
Benoit You, Christopher Purdy, Larry J Copeland, Elizabeth M Swisher, Michael A Bookman, Gini Fleming, Robert Coleman, Leslie M Randall, Krishnansu S Tewari, Bradley J...> ;Journal of Clinical Oncology. 2022 Dec 1
50 citations
Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.
Payal D. Shah, Stephanie L. Wethington, Cheyenne Pagan, Nawar A. Latif, Janos L. Tanyi, Lainie P. Martin, Mark A. Morgan, Robert A. Burger, Ashley Haggerty, Haley Zarr...> ;Gynecologic Oncology. 2021 Oct 4
1 citations
Evaluation of the management of PARP inhibitor toxicities in ovarian and endometrial cancer within a multi-institution health-system.
Rachel Hatch, Sweta U Patel, Christine Cambareri, Tanya J. Uritsky, Lainie P. Martin> ;Journal of Oncology Pharmacy Practice. 2021 Jun 17
304 citations
Ovarian cancer, version 2.2020
Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Lee-may Chen, Mihaela C. Cristea, Maria DeRosa, Eric L...> ;Journal of the National Comprehensive Cancer Network. 2021 Feb 2
8 citations
Utilization and survival outcomes of sequential, concurrent and sandwich therapies for advanced stage endometrial cancers by histology.
Emily M. Ko, Colleen M. Brensinger, Lori Cory, Robert L. Giuntoli nd, Ashley Haggerty, Nawar A. Latif, Lainie P. Martin, Mark A. Morgan, Lilie L. Lin> ;Gynecologic Oncology. 2020 Nov 1
Sources of Palliative Care Knowledge Among Patients With Advanced or Metastatic Gynecologic Cancer.
Katherine Hicks-Courant, Ashley Graul, Emily M. Ko, Robert L. Giuntoli, Lainie P. Martin, Mark A. Morgan, Ashley Haggerty> ;Journal of Pain and Symptom Management. 2021 Mar 1
232 citations
Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.
Thomas W Flaig, Philippe E Spiess, Neeraj Agarwal, Rick Bangs, Stephen A Boorjian, Mark K Buyyounouski, Sam Chang, Tracy M Downs, Jason A Efstathiou, Terence Friedland...> ;Journal of the National Comprehensive Cancer Network. 2020 Mar 1
75 citations
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with pl...
David M. O'Malley, Ursula A. Matulonis, Michael J. Birrer, Cesar M. Castro, Lucy Gilbert, Ignace Vergote, Lainie P. Martin, Gina Mantia-Smaldone, Antonio Gonzalez Mart...> ;Gynecologic Oncology. 2020 Feb 18
25 citations
Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study.
Shannon N. Westin, Michael W. Sill, Robert L. Coleman, Steven E. Waggoner, Kathleen N. Moore, Cara Mathews, Lainie P. Martin, Susan C. Modesitt, Sanghoon Lee, Zhenlin ...> ;Gynecologic Oncology. 2019 Dec 1
22 citations
Is Targeting the Folate Receptor in Ovarian Cancer Coming of Age
Michael J. Birrer, Ilaria Betella, Lainie P. Martin, Kathleen N. Moore> ;The Oncologist. 2019 Apr 1
32 citations
Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody–Drug Conjugate Mirvetuximab Soravtansine
Ursula A. Matulonis, Michael J. Birrer, David M. O'Malley, Kathleen N. Moore, Jason A. Konner, Lucy Gilbert, Lainie P. Martin, Todd M. Bauer, Amit M. Oza, Karim Malek,...> ;Clinical Cancer Research. 2019 Mar 15
4 citations
Adjuvant Chemotherapy in Uterine Leiomyosarcoma: Trends and Factors Impacting Usage.
Dhara Patel, Elizabeth Handorf, Margaret von Mehren, Lainie P. Martin, Sujana Movva> ;Sarcoma. 2019 Feb 10
58 citations
Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
Gerald Steven Falchook, Robert L. Coleman, Andrzej Roszak, Kian Behbakht, Ursula A. Matulonis, Isabelle Ray-Coquard, Piotr Sawrycki, Linda R. Duska, William P. Tew, Sh...> ;JAMA Oncology. 2019 Jan 1
9 citations
Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
Robert A. Burger, Wei Deng, Vicky Makker, Yvonne C. Collins, Heidi J. Gray, Robert Debernardo, Lainie P. Martin, Carol Aghajanian> ;Gynecologic Oncology. 2018 Sep 1
48 citations
Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in c...
Kathleen N. Moore, David M. O'Malley, Ignace Vergote, Lainie P. Martin, Antonio González-Martín, Karim Malek, Michael J. Birrer> ;Gynecologic Oncology. 2018 Oct 1
53 citations
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
Heidi J. Gray, Katherine M. Bell-McGuinn, Gini F. Fleming, Mihaela C. Cristea, Hao Xiong, Danielle Sullivan, Yan Luo, Mark D. McKee, Wijith Munasinghe, Lainie P. Martin> ;Gynecologic Oncology. 2018 Mar 1
53 citations
A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.
Kathleen N. Moore, Lainie P. Martin, David M. O'Malley, Ursula A. Matulonis, Jason A. Konner, Ignace Vergote, Jose F. Ponte, Michael J. Birrer> ;Future Oncology. 2018 Jan 1
101 citations
Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus–Related Cervical Carcinoma
Stephanie Lheureux, Marcus O. Butler, Blaise Clarke, Mihaela C. Cristea, Lainie P. Martin, Katia Tonkin, Gini F. Fleming, Anna V. Tinker, Hal W. Hirte, Daliah Tsoref, ...> ;JAMA Oncology. 2017 Nov 16
65 citations
Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion s...
Lainie P. Martin, Jason A. Konner, Kathleen N. Moore, Shelly Seward, Ursula A. Matulonis, Raymond P. Perez, Ying Su, Anna Berkenblit, Rodrigo Ruiz-Soto, Michael J. Birrer> ;Gynecologic Oncology. 2017 Nov 1
Join now to see all

Journal Articles

Phase Ib Study of Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRα)-Targeting Antibody-Drug Conjugate (ADC), in Combination with Bevacizumab in Patients with Pl...
David M O'Malley, Ursula A Matulonis, Michael J Birrer, Cesar M Castro, Lainie P Martin, Kathleen N Moore, Gynecologic Oncology

Lectures

Phase I study of carboplatin (C), pegylated liposomal doxorubicin (PLD) and everolimus (E) in platinum-sensitive epithelial ovarian, Fallopian tube or primary peritone...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018